| Carmat–France (govt): grant, 202010– grant €13m national innovation funding for clinical study of artificial heart in France from Health Ministry |
2020-10-12 |
| Priothera–Earlybird: investment, 202010 financing round Series A totalling €30m incl co-investor Earlybird Venture Capital |
2020-10-12 |
| Priothera–Fountain Healthcare Partners: investment, 202010 financing round Series A totalling €30m incl lead investor FHP |
2020-10-12 |
| Priothera–Huntsworth: public relations, 202010 service existent by Citigate Dewe Rogerson |
2020-10-12 |
| Priothera–Kyorin: mocravimod, 202010c acquisition of mocravimod from Kyorin Pharmaceutical Co Ltd |
2020-10-12 |
| Priothera–Odlander Fredrikson: investment, 202010 financing round Series A totalling €30m incl co-lead investor HealthCap |
2020-10-12 |
| Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners |
2020-10-12 |
| Priothera–Tekla Capital: investment, 202010 financing round Series A totalling €30m incl co-investor funds managed by Tekla Capital Management LLC |
2020-10-12 |
| Federation Bio–BPCE: investment, 202010 financing round Series A totalling $50m incl new + co-investor Seventure Partners/Health for Life Capital |
2020-10-06 |
| Federation Bio–SEVERAL: investment, 202010 financing round Series A $50m led by Horizons Ventures + incl Seventure Partners + Venrock + Altitude |
2020-10-06 |
| Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis |
2020-10-06 |
| BIA Separations–Sartorius: investment, 202010– acquisition €240m in cash + €120m in SSB shares BIA to be merged into SSB ANNOUNCED |
2020-10-02 |
| Sophia Genetics–Eurazeo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Eurazeo Growth |
2020-10-01 |
| Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Venturse |
2020-09-25 |
| Bellevue–SEVERAL: investment, 202009 Closing $170m of BB Pureos Bioventures LP fund |
2020-09-23 |
| Lava Therapeutics–Sanofi: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Sanofi Ventures |
2020-09-17 |
| ImCheck Therapeutics–Bellevue: investment, 202009 financing round Series B extension €6m from BB Pureos Bioventures bringing total Series B to €54m |
2020-09-15 |
| Evotec–BIOASTER: antiinfectives, 202009– collab research to establish tech + innovation hub in Lyon work started in early 2020 |
2020-09-14 |
| Neogene Therapeutics–Jeito Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Jeito Capital |
2020-09-14 |
| Neogene Therapeutics–SEVERAL: investment, 202009 financing round Series A $110m co-led by EcorR1 Capital + Jeito Capital + Syncona |
2020-09-14 |
| Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares |
2020-08-19 |
| Principia Biopharma–Sanofi: investment, 202008– acquisition $3.68b cash tender offer at $100/share |
2020-08-17 |
| Genkyotex–Calliditas Therapeutics: investment, 202008– acquisition in two steps for €32.3m in cash + €55m milestones (contingent rights) ANNOUNCED |
2020-08-13 |
| T-Knife–SEVERAL: investment, 202008 financing round Series A €66m co-led by Versant Ventures + RA Capital |
2020-08-06 |
| DNA Script–SEVERAL: investment, 202007 financing round Series B extension $50m led by Casdin Capital |
2020-07-29 |
| Enthera–SEVERAL: investment, 202007 financing round Series A €28m co-led by Sofinnova Partners + AbbVie Ventures |
2020-07-28 |
| Enthera–Sofinnova: investment, 202007 financing round Series A totalling €28m incl existing + co-lead investor Sofinnova Partners |
2020-07-28 |
| Tubulis–BPCE: investment, 202007 financing round Series A totalling €10.7m incl co-investor Seventure Partners |
2020-07-21 |
| Tubulis–SEVERAL: investment, 202007 financing round Series A €10.7m co-led by BioMedPartners + HTGF |
2020-07-21 |
| Enancio–Illumina: acquisition, 202007 acquisition of Enancio by Illumina |
2020-07-14 |
| Osivax–Trophic Communications: public relations, 202007 service existent by Trophic Communications |
2020-07-08 |
| Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties |
2020-07-08 |
| Citryll–BPCE: investment, 202007 financing round Series A totalling €18.5m incl new + lead investor Seventure incl its Health for Capital II fund |
2020-07-02 |
| Citryll–SEVERAL: investment, 202007 financing round Series A €18.5m led by Seventure + co-led by BioGeneration Ventures |
2020-07-02 |
| Lysogene–Weizmann Institute: gene therapy, 202007– collab research + license option AAV gene therapy for Gaucher + Parkinson diseases |
2020-07-01 |
| Resolution Spectra Systems–Merck (DE): investment, 202007 acquisition €na of Resolution Spectra Systems by Merck |
2020-07-01 |
| Enterome–BPCE: investment, 202006 financing round Series E €na incl existing investor Seventure Health for Life Capital |
2020-06-25 |
| Enterome–Nestlé: investment, 202006 financing round Series E €na incl existing investor Nestlé Health Science |
2020-06-25 |
| Enterome–Omnes Capital: investment, 202006 financing round Series E €na incl existing investor Omnes Capital |
2020-06-25 |
| Enterome–Principia SGR: investment, 202006 financing round Series E €na incl existing investor Principia |
2020-06-25 |
| Enterome–SEVERAL: investment, 202006 financing round Series E €na with existing plus new investors SymBiosis LLC + Takeda Pharma |
2020-06-25 |
| Enterome–SymBiosis LLC: investment, 202006 financing round Series E €na incl new investor SymBiosis LLC |
2020-06-25 |
| Enterome–Takeda: investment, 202006 financing round Series E €na incl new investor Takeda Pharmaceutical Co Ltd |
2020-06-25 |
| RareCyte–Scienion: single-cell dispenser, 202006 supply existent of cellenONE to RareCyte for CTC analysis technology by Cellenion |
2020-06-22 |
| DiogenX–Advent France Biotechnology: investment, 202006 seed financing round totalling €4.5m incl investor Advent France Biotechnology |
2020-06-16 |
| DiogenX–Andrew Lloyd Associates: public relations, 202006 service existent by ALA |
2020-06-16 |
| DiogenX–Boehringer: investment, 202006 seed financing round totalling €4.5m incl investor BIVF |
2020-06-16 |
| DiogenX–Juvenile Diabetes Research Foundation: investment, 202006 seed financing round totalling €4.5m incl investor JDRF T1D Fund |
2020-06-16 |
| DiogenX–SEVERAL: investment, 202006 seed financing round €4.5m from Advent France Biotechnology + BIVF + JDRF T1D Fund |
2020-06-16 |
| eTheRNA–BNP Paribas: investment, 202006 financing round Series B totalling €34m incl new investor BNP Paribas Fortis Equity |
2020-06-16 |
| MedinCell–SEVERAL: investment, 202006 capital increase €15.6m from French + international investors |
2020-06-16 |
| Ona Therapeutics–France (govt): investment, 202006 financing round Series A totalling €30m incl new investor Bpifrance InnoBio 2 |
2020-06-16 |
| Ona Therapeutics–SEVERAL: investment, 202006 financing round Series A €30m |
2020-06-16 |
| Epsilen Bio–Sofinnova: investment, 202006c seed financing €2.3m from Sofinnova Partners through Sofinnova Telethon Fund |
2020-06-15 |
| Corvidia Therapeutics–Novo Group: investment, 202006 acquisition $725m upfront cash + $1.375b milestones cash by Novo Nordisk ANNOUNCED |
2020-06-11 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Belfius Insurance |
2020-06-10 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor FPIM |
2020-06-10 |
| Bioqube Ventures–EU (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor EIF |
2020-06-10 |
| Bioqube Ventures–Flanders (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor PMV |
2020-06-10 |
| Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab |
2020-06-10 |
| Bioqube Ventures–JnJ: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor JnJ Innovation |
2020-06-10 |
| Bioqube Ventures–Molenwater Groep: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Molenwater Groep |
2020-06-10 |
| Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al |
2020-06-10 |
| Protera–SEVERAL: investment, 202006 financing round Series A $5.6m led by Sofinnova Partners + incl existing investor SOSV |
2020-06-10 |
| NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures |
2020-06-03 |
| MedinCell–SEVERAL: credit, 202005– state guaranteed PGE loan €10.9m at 0.25% up to 5y from Banque Populaire du Sud + BNP Paribas |
2020-05-27 |
| Tollys–Andrew Lloyd Associates: public relations, 202005 service existent by ALA |
2020-05-26 |
| Tollys–SEVERAL: investment, 202005 financing round Series A €2.3m bringing total raised since founding 2015 to €6.4m |
2020-05-26 |
| Poxel–Trophic Communications: public relations, 202005 service existent IR+ media EU/US by Trophic Communications |
2020-05-25 |
| Regeneron–Sanofi: investment, 202005 DIVESTMENT $11.7b of 22.8m shares at $515/share with Sanofi retaining 400k shares |
2020-05-25 |
| HotSpot Therapeutics–SEVERAL: investment, 202005 financing round Series B $65m led by SR One |
2020-05-21 |
| HotSpot Therapeutics–Sofinnova: investment, 202005 financing round Series B totalling $65m incl existing + co-investor Sofinnova Partners |
2020-05-21 |
| Genespire–San Raffaele: gene therapy, 2002005– collab strategic alliance development of gene therapies with SR-Tiget |
2020-05-13 |
| ElsaLys–Mediolanum: investment, 202005 acquisition of ElsaLys Biotech by Mediolanum Farmaceutici SpA |
2020-05-07 |
| Vaxxel–Transgene: cell line technology, 202005 acquisition €na of DuckCelt-T17 cell line from Transgene incl shareholding for Transgene |
2020-05-04 |
| Vaxxel–Transgene: investment, 202005 investment €na Transgene becomes shareholder as part of acquisition of DuckCelt-T17 cell line by Vaxxel |
2020-05-04 |
| Lifebit–Eurazeo: investment, 202004 financing round Series totalling £6m incl new + lead investor Idinvest Partners |
2020-04-30 |
| Lifebit–SEVERAL: investment, 202004 financing round Series £6m led by new investor Idinvest Partners |
2020-04-30 |
| Pfizer–Valneva: Lyme disese vaccine, 202004– collab developm of VLA15 + commerc by Pfizer $130m upfront + $178m milestones + 2-digit tiered royalties |
2020-04-30 |
| PinCell–SEVERAL: investment, 202004 seed financing round €1.65m led by Sofinnova Telethon Fund |
2020-04-30 |
| PinCell–Sofinnova: investment, 202004 seed financing round totalling €1.65m incl lead investor Sofinnova Telethon Fund |
2020-04-30 |
| Genespire–Sofinnova: investment, 202004 Series A financing €16m from Sofinnova Partners |
2020-04-29 |
| Kurma–EU (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor EIF |
2020-04-29 |
| Kurma–Institut Pasteur: investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor Pasteur Institute |
2020-04-29 |
| Kurma–North Rhine-Westphalia (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor NRW.BANK |
2020-04-29 |
| Kurma–SEVERAL: investment, 202004 final closing of Kurma Biofund III with €160m |
2020-04-29 |
| MicroPort Scientific–Robocath: cardiovascular devices, 202004– collab strategic agreem to set up joint venture in China for vascular robotics platform |
2020-04-29 |
| Polyplus-transfection–Warburg Pincus: investment, 202004 investment resulting in Warburg Pincus + ArchiMed owning equal shares + voting rights |
2020-04-29 |
| Robocath–MicroPort Scientific: investment, 202004 financing round Series C totalling €40m incl new + lead investor MicroPort Scientific Corp |
2020-04-29 |
| Robocath–SEVERAL: investment, 202004 financing round Series C €40m led by MicroPort Scientific |
2020-04-29 |
| Gustave Roussy–Biognosys: MS-based proteomics, 202004– collab using proteomic profiling in attempt to repurpose tocilizumab for Covid-19 |
2020-04-28 |
| BrainVectis–AskBio: investment, 202004 acquisition €na of BrainVectis by Asklepios BioPharmaceutical |
2020-04-22 |
| EnginZyme–SEVERAL: investment, 202004 financing round Series A €6.4m led by Sofinnova Partners |
2020-04-22 |
| EnginZyme–Sofinnova: investment, 202004 financing round Series A totalling €6.4m incl lead investor Sofinnova Industrial Biotech Fund |
2020-04-22 |
| Valneva–Dynavax: SARS-CoV-2 vaccine, 202004– collab development combining Valneva’s vaccine technology with adjuvant CpG 1018 of Dynavax |
2020-04-22 |
| LNC Therapeutics–Univ Valencia: microbiomic treatment, 202004– license ww excl for patent on Christensenella therapeutics for mood disorders |
2020-04-15 |
| Servier–Gorrissen Federspiel: legal services, 202004 supply service Gorrissen Federspiel legal advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Servier–Lazard: financial services, 202004 supply service Lazard financial advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Servier–McDermott Will & Emery: legal services, 202004 supply service MWE legal advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Symphogen–Perkins Coie: legal services, 202004 supply service Perkins Coie legal advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
![[LSF] Life-Sciences-France.com - The French Life Sciences Web Portal](/images/basics/lsf-life-sciences-france-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
